349 related articles for article (PubMed ID: 31327655)
21. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
22. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
23. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
24. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract][Full Text] [Related]
26. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
27. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
28. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models.
Zollo M; Di Dato V; Spano D; De Martino D; Liguori L; Marino N; Vastolo V; Navas L; Garrone B; Mangano G; Biondi G; Guglielmotti A
Clin Exp Metastasis; 2012 Aug; 29(6):585-601. PubMed ID: 22484917
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.
Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L
Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367
[TBL] [Abstract][Full Text] [Related]
30. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.
Lu H; Bowler N; Harshyne LA; Craig Hooper D; Krishn SR; Kurtoglu S; Fedele C; Liu Q; Tang HY; Kossenkov AV; Kelly WK; Wang K; Kean RB; Weinreb PH; Yu L; Dutta A; Fortina P; Ertel A; Stanczak M; Forsberg F; Gabrilovich DI; Speicher DW; Altieri DC; Languino LR
Matrix Biol; 2018 Sep; 70():20-35. PubMed ID: 29530483
[TBL] [Abstract][Full Text] [Related]
31. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
[TBL] [Abstract][Full Text] [Related]
32. WHSC1/NSD2 regulates immune infiltration in prostate cancer.
Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
[TBL] [Abstract][Full Text] [Related]
33. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
[TBL] [Abstract][Full Text] [Related]
34. BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1.
Hu J; Sun F; Chen W; Zhang J; Zhang T; Qi M; Feng T; Liu H; Li X; Xing Y; Xiong X; Shi B; Zhou G; Han B
J Exp Clin Cancer Res; 2019 May; 38(1):227. PubMed ID: 31138311
[TBL] [Abstract][Full Text] [Related]
35. HepG2 cells acquire stem cell-like characteristics after immune cell stimulation.
Wang H; Yang M; Lin L; Ren H; Lin C; Lin S; Shen G; Ji B; Meng C
Cell Oncol (Dordr); 2016 Feb; 39(1):35-45. PubMed ID: 26650484
[TBL] [Abstract][Full Text] [Related]
36. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Proctor E; Waghray M; Lee CJ; Heidt DG; Yalamanchili M; Li C; Bednar F; Simeone DM
PLoS One; 2013; 8(2):e55820. PubMed ID: 23437065
[TBL] [Abstract][Full Text] [Related]
37. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.
Zhang L; Jiao M; Li L; Wu D; Wu K; Li X; Zhu G; Dang Q; Wang X; Hsieh JT; He D
J Cancer Res Clin Oncol; 2012 Apr; 138(4):675-86. PubMed ID: 22237455
[TBL] [Abstract][Full Text] [Related]
38. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
39. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
[TBL] [Abstract][Full Text] [Related]
40. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.
Mizutani K; Sud S; McGregor NA; Martinovski G; Rice BT; Craig MJ; Varsos ZS; Roca H; Pienta KJ
Neoplasia; 2009 Nov; 11(11):1235-42. PubMed ID: 19881959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
